REFERENCES
1. Morice M, Serruys P, Sousa E. A randomized comparison of a sirolimus eluting stent with a standard stent for coronary revascularization. ACC Current Journal Review 2002;11:61.
2. Neumann FJ, Sousa-Uva M. ‘Ten commandments’ for the 2018 ESC/EACTS guidelines on myocardial revascularization. Eur Heart J 2019;40:79-80.
3. Costopoulos C, Latib A, Naganuma T, et al. The role of drug-eluting balloons alone or in combination with drug-eluting stents in the treatment of de novo diffuse coronary disease. JACC Cardiovasc Interv 2013;6:1153-9.
4. van Beek KAJ, van Steenbergen GJ, Vervaat FE, et al. Single center experience in the treatment of hemodynamically significant diffuse coronary artery disease of the left anterior descending. Int J Cardiol 2022;352:40-4.
5. Cortese B, Sanchez-Jimenez E. Back to the future: DCB use instead of DES for the treatment of complex, native coronary artery disease. Eur Heart J Suppl 2021;23:E63-7.
6. Youn YJ, Jeon HS, Kim YI, et al. Impact of the ultra-long 48 mm drug-eluting stent on procedural and clinical outcomes in patients with diffuse long coronary artery disease. Clin Cardiol 2023;46:416-24.
7. Brugaletta S, Gomez-Lara J, Ortega-Paz L, et al. 10-year follow-up of patients with everolimus-eluting versus bare-metal stents after ST-segment elevation myocardial infarction. J Am Coll Cardiol 2021;77:1165-78.
8. Kufner S, Ernst M, Cassese S, et al. ISAR-TEST-5 Investigators. 10-year outcomes from a randomized trial of polymer-free versus durable polymer drug-eluting coronary stents. J Am Coll Cardiol 2020;76:146-58.
9. Shlofmitz E, Iantorno M, Waksman R. Restenosis of drug-eluting stents: a new classification system based on disease mechanism to guide treatment and state-of-the-art review. Circ Cardiovasc Interv 2019;12:e007023.
10. Chen Z, Matsumura M, Mintz GS, et al. Prevalence and impact of neoatherosclerosis on clinical outcomes after percutaneous treatment of second-generation drug-eluting stent restenosis. Circ Cardiovasc Interv 2022;15:e011693.
11. Konigstein M, Madhavan MV, Ben-Yehuda O, et al. Incidence and predictors of target lesion failure in patients undergoing contemporary DES implantation-individual patient data pooled analysis from 6 randomized controlled trials. Am Heart J 2019;213:105-11.
12. Cassese S, Byrne RA, Tada T, et al. Incidence and predictors of restenosis after coronary stenting in 10 004 patients with surveillance angiography. Heart 2014;100:153-9.
13. Alfonso F, Coughlan JJ, Giacoppo D, Kastrati A, Byrne RA. Management of in-stent restenosis. EuroIntervention 2022;18:e103-23.
14. Généreux P, Rutledge DR, Palmerini T, et al. Stent thrombosis and dual antiplatelet therapy interruption with everolimus-eluting stents: insights from the xience V coronary stent system trials. Circ Cardiovasc Interv 2015;8:e001362.
15. Taniwaki M, Radu MD, Zaugg S, et al. Mechanisms of very late drug-eluting stent thrombosis assessed by optical coherence tomography. Circulation 2016;133:650-60.
16. Condello F, Spaccarotella C, Sorrentino S, Indolfi C, Stefanini GG, Polimeni A. Stent thrombosis and restenosis with contemporary drug-eluting stents: predictors and current evidence. J Clin Med 2023;12:1238.
17. Lee CW, Ahn JM, Lee JY, et al. OPERA Steering Committee and Investigators. Long-term (8 year) outcomes and predictors of major adverse cardiac events after full metal jacket drug-eluting stent implantation. Catheter Cardiovasc Interv 2014;84:361-5.
18. Kjøller-Hansen L, Kelbæk H, Christiansen EH, et al. Predictors of 10-year stent-related adverse outcomes after coronary drug-eluting stent implantation: the importance of stent size. Cardiology 2021;146:705-12.
19. Kong MG, Han JK, Kang JH, et al. Collaborators. Clinical outcomes of long stenting in the drug-eluting stent era: patient-level pooled analysis from the GRAND-DES registry. EuroIntervention 2021;16:1318-25.
20. Lee CH, Kang DY, Han M, et al. IRIS-DES Registry Investigators. Differential cutoff points and clinical impact of stent parameters of various drug-eluting stents for predicting major adverse clinical events: an individual patient data pooled analysis of seven stent-specific registries and 17,068 patients. Int J Cardiol 2019;282:17-23.
21. Coughlan JJ, Aytekin A, Koch T, et al. Long-term clinical outcomes after drug eluting stent implantation with and without stent overlap. Catheter Cardiovasc Interv 2022;99:541-51.
22. Şaylık F, Çınar T, Selçuk M, Çiçek V, Hayıroğlu MI, Orhan AL. Comparison of outcomes between single long stent and overlapping stents: a meta-analysis of the literature. Herz 2023.
23. Mangner N, Farah A, Ohlow MA, et al. BASKET-SMALL 2 Investigators. Safety and efficacy of drug-coated balloons versus drug-eluting stents in acute coronary syndromes: a prespecified analysis of BASKET-SMALL 2. Circ Cardiovasc Interv 2022;15:e011325.
24. Mahfoud F, Farah A, Ohlow MA, et al. Drug-coated balloons for small coronary artery disease in patients with chronic kidney disease: a pre-specified analysis of the BASKET-SMALL 2 trial. Clin Res Cardiol 2022;111:806-15.
25. Cortese B, Di Palma G, Guimaraes MG, et al. Drug-coated balloon versus drug-eluting stent for small coronary vessel disease: PICCOLETO II randomized clinical trial. JACC Cardiovasc Interv 2020;13:2840-9.
26. El-Mokdad R, di Palma G, Cortese B. Long-term follow-up after sirolimus-coated balloon use for coronary artery disease. Final results of the Nanolutè study. Catheter Cardiovasc Interv 2020;96:E496-500.
27. Yu X, Wang X, Ji F, et al. A non-inferiority, randomized clinical trial comparing paclitaxel-coated balloon versus new-generation drug-eluting stents on angiographic outcomes for coronary de novo lesions. Cardiovasc Drugs Ther 2022;36:655-64.
28. Uskela S, Kärkkäinen JM, Eränen J, et al. Percutaneous coronary intervention with drug-coated balloon-only strategy in stable coronary artery disease and in acute coronary syndromes: an all-comers registry study. Catheter Cardiovasc Interv 2019;93:893-900.
29. Rosenberg M, Waliszewski M, Chin K, et al. Prospective, large-scale multicenter trial for the use of drug-coated balloons in coronary lesions: the DCB-only All-Comers registry. Catheter Cardiovasc Interv 2019;93:181-8.
30. Rosenberg M, Waliszewski M, Krackhardt F, et al. Drug coated balloon-only strategy in de novo lesions of large coronary vessels. J Interv Cardiol 2019;2019:6548696.
31. Yamamoto T, Sawada T, Uzu K, Takaya T, Kawai H, Yasaka Y. Possible mechanism of late lumen enlargement after treatment for de novo coronary lesions with drug-coated balloon. Int J Cardiol 2020;321:30-7.
32. Basavarajaiah S, Latib A, Shannon J, et al. Drug-eluting balloon in the treatment of in-stent restenosis and diffuse coronary artery disease: real-world experience from our registry. J Interv Cardiol 2014;27:348-55.
33. Basavarajaiah S, Athukorala S, Kalogeras K, et al. Mid-term clinical outcomes from use of Sirolimus coated balloon in coronary intervention; data from real world population. Catheter Cardiovasc Interv 2021;98:57-65.
34. Ielasi A, Miyazaki T, Geraci S, et al. Hybrid strategy with a bioresorbable scaffold and a drug-coated balloon for diffuse coronary artery disease: the “no more metallic cages” multicentre pilot experience. EuroIntervention 2016;11:e1589-95.
35. Merinopoulos I, Gunawardena T, Wickramarachchi U, et al. Long-term safety of paclitaxel drug-coated balloon-only angioplasty for de novo coronary artery disease: the SPARTAN DCB study. Clin Res Cardiol 2021;110:220-7.
36. Yang YX, He KZ, Li JY, et al. Comparisons of drug-eluting balloon versus drug-eluting stent in the treatment of young patients with acute myocardial infarction. J Cardiovasc Dev Dis 2023;10:29.
37. Wickramarachchi U, Corballis NH, Maart CA, Gilbert TJ, Eccleshall SC, et al. 24 drug coated balloon-only angioplasty in chronic total occlusions, a UK single centre experience. Heart 2017;103:A11. Available from: https://heart.bmj.com/content/103/Suppl_7/A11.1. [Last accessed on 10 Jul 2023]
38. Köln PJ, Scheller B, Liew HB, et al. Treatment of chronic total occlusions in native coronary arteries by drug-coated balloons without stenting - a feasibility and safety study. Int J Cardiol 2016;225:262-7.
39. Jun EJ, Shin ES, Teoh EV, et al. Clinical outcomes of drug-coated balloon treatment after successful revascularization of de novo chronic total occlusions. Front Cardiovasc Med 2022;9:821380.
40. Pan L, Lu W, Han Z, et al. Clinical outcomes of drug-coated balloon in coronary patients with and without diabetes mellitus: a multicenter, propensity score study. J Diabetes Res 2021;2021:5495219.
41. Ielasi A, Buono A, Pellicano M, et al. A hybrid approach evaluating a drug-coated balloon in combination with a new-generation drug-eluting stent in the treatment of de novo diffuse coronary artery disease: the HYPER pilot study. Cardiovasc Revasc Med 2021;28:14-9.
42. Yang X, Lu W, Pan L, et al. Long-term outcomes of drug-coated balloons in patients with diffuse coronary lesions. Front Cardiovasc Med 2022;9:935263.
43. Shin ES, Jun EJ, Kim S, et al. Clinical impact of drug-coated balloon-based percutaneous coronary intervention in patients with multivessel coronary artery disease. JACC Cardiovasc Interv 2023;16:292-9.
44. Corrigendum to: paclitaxel-coated balloon angioplasty vs. drug-eluting stenting for the treatment of coronary in-stent restenosis: a comprehensive, collaborative, individual patient data meta-analysis of 10 randomized clinical trials (DAEDALUS study). Eur Heart J 2020;41:3728.
